drugset
drugset / Trial / NCT05418712

A Microneurography (MNG) Study of VX-150 in Healthy Participants

NCT05418712 ↗

Phase 1 Completed 45 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if C fiber conduction is impacted by NAV1.8 modulation.

Timeline

Start
2022-06-16
Primary completion
2022-09-14
Completion
2022-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-150 Unknown — Oral

Indications

No indication recorded.